Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zhejiang Weishi Biotechnology is a high-tech enterprise specializing in high-throughput single-cell analysis and digital PCR technologies. The company provides integrated solutions including microfluidic chips, automated instruments, and specialized reagents for precision medicine and life science research. Their core technology focuses on the precise manipulation and analysis of single cells and molecules, enabling breakthroughs in liquid biopsy and single-cell sequencing. Headquartered in Hangzhou, China, Weishi Biotech serves hospitals, research institutes, and pharmaceutical companies. The company's product portfolio includes the MicroDrop series of digital PCR systems and single-cell sorting platforms. By bridging advanced microfluidics with clinical needs, they aim to improve diagnostic accuracy in oncology and infectious diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zhejiang Weishi Biotechnology.